Bioenergetics-Driven Extracellular Vesicle Therapies for Heart Failure: From Preclinical Insights to Regenerative Translation

Figure 1. System-Level EV-Mediated Bioenergetic Reprogramming in Heart Failure. The schematic depicts extracellular vesicles (EVs) as central mediators of bioenergetic communication across the failing cardiac ecosystem. EV cargo, including microRNAs, proteins, lipids, and mitochondrial regulatory factors, modulates mitochondrial respiration, ATP production, redox homeostasis, and mitochondrial quality control within recipient cardiomyocytes. Simultaneously, EV-mediated signaling influences endothelial cells by enhancing angiometabolic coupling and substrate delivery, promotes reparative immune cell polarization that reduces inflammatory metabolic stress, and suppresses fibroblast activation associated with energetically unfavorable remodeling. Through these coordinated multicellular interactions, EVs improve myocardial energetic efficiency and metabolic resilience at the tissue and organ level. The figure illustrates the central concept that therapeutic EVs act as system-wide bioenergetic regulators rather than single-target molecular interventions.

Figure 2. Extracellular Vesicle-Mitochondrial Bioenergetic Axis Across Heart Failure Phenotypes: An Integrated Source–Mechanism–Disease Framework. This flow integrates extracellular vesicle (EV) origin, mitochondrial bioenergetics, and cardiovascular phenotype into a unified axis-based model. 1. EVs are stratified by cellular source—stem cell-derived EVs enriched in regenerative and pro-survival cargo, platelet-derived EVs mediating thrombo-inflammatory and vascular signaling, cardiac-derived EVs reflecting myocardial stress and injury responses, and tissue-derived EVs contributing systemic metabolic–inflammatory cross-talk. 2. These EVs converge on key mitochondrial regulatory nodes, including biogenesis (PGC-1α/NRF1), mitophagy (PINK1/Parkin), ATP production via oxidative phosphorylation, and ROS homeostasis through antioxidant pathways such as Nrf2, with dysregulation leading to progressive energetic failure. 3. The resulting mitochondrial state determines clinical expression across heart failure phenotypes, where HFrEF is dominated by ATP depletion and oxidative stress-driven contractile dysfunction, HFpEF by inflammation-associated energetic inefficiency and impaired relaxation, and…

Figure 3. Scaling EV Bioenergetic Effects from Preclinical Models to Heart Failure Phenotypes. This schematic illustrates the progressive scaling of extracellular vesicle (EV)-mediated bioenergetic effects from reductionist preclinical systems to clinically relevant heart failure phenotypes, with the blue-to-gold color gradient representing the transition from in vitro discovery to large-animal and human clinical translation. The top circular icons depict the tracking and delivery of EV components across systems. At the cellular level, EVs enhance mitochondrial respiration, normalize redox balance, and improve ATP efficiency in stressed cardiomyocytes and nonmyocyte populations. These bioenergetic gains translate in small-animal models into measurable improvements in mitochondrial oxygen consumption (20–50%), reductions in oxidative stress, and modest but reproducible increases in cardiac function (e.g., ejection fraction) [3,4]. Validation in large-animal models demonstrates preservation of myocardial energetic reserve, attenuation of fibrotic remodeling (indicated by ↑ fibrotic area text and accompanying tissue quantification graphs), and improved mechanical efficiency under…

Figure 4. Conceptual framework for the clinical translation of EV-based bioenergetic therapy in heart failure. The schematic illustrates a stepwise pathway from patient stratification based on metabolic phenotype, through EV dosing logic defined by functional bioenergetic potency, to biomarker-guided assessment and energy-centric clinical endpoints. Patient stratification is proposed to identify who benefits energetically, not just clinically. EV design and dosing logic reinforce functional potency over particle number. Bioenergetic biomarkers show energy-centric pharmacodynamics. Marking clinical and functional endpoints helps reframe success beyond EF alone. Integration with GDMT positions EVs as a bioenergetic layer, not a replacement. Integration with guideline-directed medical therapy is emphasized, positioning EVs as a complementary bioenergetic layer capable of enhancing myocardial efficiency and systemic metabolic coordination across heart failure phenotypes. A future translational paradigm may involve EV administration as an adjunct to optimized GDMT, analogous to how contemporary HF management employs layered therapeutic strategies targeting complementary biological mechanisms.…